1. Home
  2. ZYME vs PEB Comparison

ZYME vs PEB Comparison

Compare ZYME & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.58

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Pebblebrook Hotel Trust of Beneficial Interest

PEB

Pebblebrook Hotel Trust of Beneficial Interest

HOLD

Current Price

$11.34

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZYME
PEB
Founded
2003
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2017
2009

Fundamental Metrics

Financial Performance
Metric
ZYME
PEB
Price
$26.58
$11.34
Analyst Decision
Strong Buy
Hold
Analyst Count
8
8
Target Price
$28.00
$12.19
AVG Volume (30 Days)
1.9M
2.0M
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
0.35%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$134,481,000.00
$1,464,126,000.00
Revenue This Year
$65.21
$2.25
Revenue Next Year
$20.39
$2.96
P/E Ratio
N/A
N/A
Revenue Growth
116.21
0.99
52 Week Low
$9.03
$7.42
52 Week High
$28.49
$15.12

Technical Indicators

Market Signals
Indicator
ZYME
PEB
Relative Strength Index (RSI) 73.43 57.59
Support Level $21.89 $10.46
Resistance Level $28.49 $11.58
Average True Range (ATR) 1.53 0.35
MACD 0.65 0.06
Stochastic Oscillator 84.61 74.79

Price Performance

Historical Comparison
ZYME
PEB

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About PEB Pebblebrook Hotel Trust of Beneficial Interest

Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.

Share on Social Networks: